Clinical trial NCT02051023: Efficacy and Safety of Fluorometholone (FML) in Dry Eye Disease (Keratoconjunctivitis Sicca)
Official title: Randomized, Double-Masked, Vehicle-controlled Phase III Trial on the Safety/Efficacy of FML® 0.1% in the Treatment of the Inflammatory Exacerbation Provoked by Exposure to an Adverse Controlled Environment in Patients With Dry Eye Disease
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Dry Eye
Keywords: keratoconjunctivitis sicca
dry eye
dry eye syndrome
dry eye disease
steroids
Lead sponsor: Instituto Universitario de Oftalmobiología Aplicada (Institute of Applied Ophthalmobiology) - IOBA
Sponsor class: OTHER
First posted: 2014-01-31
Enrollment: 41
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Hypothesis: Fluorometholone (FML) 0.1% eyedrops topically applied 4 times a day for 22 days is more efficient than artificial tears (Liquifilm) in dry eye disease (DED) and ameliorates the worsening of the disease after exposure to an adverse controlled environment.

Detailed description: There will be 4 visits in 3 different days:

Visit 1 (V1). Inclusion in normalized controlled environment (NCE)

Visit 2 (V2). 21 days post-treatment. Data collected in NCE

Visit 3 (V3). 21 days post-treatment. Data collected in adverse controlled environment (ACE)

Visit 4 (V4). 22 days post-treatment. Recovery visit in ACE. Data collected in NCE

Eligibility criteria: Inclusion Criteria:

* Age \> 18 years
* Signed informed consent
* Subjects refer worsening in their pathologies when exposed to adverse environmental conditions in their daily life
* Fluorescein corneal staining ≥ 1in Oxford Scale
* Ocular surface disease index (OSDI) test \> 12
* Tear breakup Time (TBT) ≤ 7 seconds in both eyes
* Schirmer test without anesthesia ≤ 10 mm in 5 minutes in both eyes
* Any concomitant medication that may affect dry eye syndrome, ocular surface or vision, must have started at least 3 months before screening visit, and there are no changes in dose expected during the study duration.
* Best corrected visual acuity at least 0.1 logMar at 6 meters with both eyes
* Current use of ophthalmic artificial tears at study inclusion.
* Signed informed consent
* Signed data protection consent

Exclusion Criteria:

* Sensitivity or known intolerance to any of the products used in the study
* Previous severe ocular inflammation or infections in the 6 previous months to study inclusion
* Any ocular pathology other than dry eye syndrome or atopic keratoconjunctivitis
* Any ocular surgery or trauma that may affect corneal sensitivity and / or normal tear distribution (refractive or cataract surgery) in the 6 previous months or any ocular or systemic surgery planned during the study duration that may affect the study as assessed by principal investigator.
* Use of contact lenses in the 3 previous months to study inclusion
* Use of any topical medication for pathologies other than dry eye syndrome.
* Any ocular topical treatment for dry eye syndrome with corticosteroids or non steroid anti-inflammatory drugs must have stopped 1 month before study inclusion. Any treatment with topical cyclosporin must have been stopped 3 months before study inclusion.
* Any uncontrolled severe systemic disease that may affect the eye (except for Sjögren Syndrome)
* Start, discontinuation or dose change during the study of antihistaminic, cholinergic agents, beta blockers, antidepressants or any other systemic medications with potential effect over tear film.
* Start of any systemic treatment that may affect dry eye syndrome, vision, ocular surface or intraocular pressure during the 3 previous months to study inclusion.
* Surgical / non surgical tear point occlusion in the 3 previous months to study inclusion or prevision during study duration for this procedure.
* Cup / disc ratio \> 0.6
* History of intraocular pressure \> 22 mm Hg within 2 months previous to study inclusion
* Pregnancy or breastfeeding women
* Inclusion in another research study in the previous 30 days to study inclusion

Primary outcomes:
measure: Fluorescein corneal staining
timeFrame: 22 days
measure: Symptom Assessment in Dry Eye (SANDE) I and II questionnaire
timeFrame: 22 days
Secondary outcomes:
measure: Tear inflammatory molecule levels
timeFrame: 22 days
measure: Best corrected visual acuity
timeFrame: 22 days
measure: Biomicroscopy findings at slit lamp examination
timeFrame: 22 days
measure: Adverse events during the trial
timeFrame: 22 days
measure: Other Efficacy Measures
timeFrame: 22 days
measure: Intraocular pressure (IOP) and fundus examination
timeFrame: 22 days
Other outcomes:
Locations:
city: Valladolid
country: Spain
facility: IOBA (Instituto de Oftalmobiología Aplicada), University of Valladolid
city: Valladolid
country: Spain
facility: IOBA
Study officials:
affiliation: Ocular surface group Director - IOBA
name: Margarita Calonge-Cano, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References: